格隆汇8月1日丨南京医药(600713.SH)公布，截至2025年7月31日，公司通过集中竞价交易方式已累计回 购公司股份1,629.9951万股，占公司2025年7月末总股本的比例为1.25%。累计回购公司股份数与上次披 露数相比没有变化，回购成交的最高价为5.22元/股，最低价为4.69元/股，已支付的资金总额为8,025.76 万元（不含交易费用）。 ...

Core Viewpoint - Nanjing Pharmaceutical (600713.SH) has repurchased a total of 16.299951 million shares, representing 1.25% of the total share capital as of July 31, 2025 [1] Summary by Category Share Repurchase - The company has conducted share repurchases through centralized bidding, with no change in the cumulative number of shares repurchased compared to the last disclosure [1] - The highest price for the repurchased shares was 5.22 CNY per share, while the lowest price was 4.69 CNY per share [1] - The total amount of funds paid for the repurchase, excluding transaction fees, was 80.2576 million CNY [1]

证券代码：600713 证券简称：南京医药 公告编号：ls2025-099 债券代码：110098 债券简称：南药转债 2025 年 3 月 14 日，南京医药股份有限公司（以下简称"公司"）召开第九届 董事会 2025 年第一次临时会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司以自有资金或自筹资金通过集中竞价交易方式回购公 司股份，用于实施 2025 年限制性股票激励计划。本次回购的资金总额不低于人民 币 7,000 万元（含）且不超过人民币 13,158 万元（含）；回购价格不超过人民币 7.31 元/股（含）；回购期限为自公司董事会审议通过本次回购股份方案之日起不超过 12 个月。详情请见公司于 2025 年 3 月 15 日对外披露的编号为 ls2025-021 之《南 京医药股份有限公司关于以集中竞价交易方式回购股份方案的公告》，以及于 2025 年 3 月 26 日对外披露的编号为 ls2025-030 之《南京医药股份有限公司关于以集中 竞价交易方式回购股份的回购报告书》。 南京医药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保 ...

| | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 1 | | 款 | | | | | | --- | --- | --- | --- | --- | --- | | 5 | 招商银行单位大额存单 | 15,000.00 | - | - | 15,000.00 | | | 年第 期 2025 281 | | | | | | | 平安银行对公结构性存 | | | | | | 6 | 款（100%保本挂钩汇率） 14 天型产品 | 14,200.00 | 6,000.00 | 14.9893 | 8,200.00 | | 7 | 民生银行聚赢股票-挂钩 挂钩沪深 指数结构 300 | 20,000.00 | 20,000.00 | 80.06 | - | | | 性存款 | | | | | | 8 | 招商银行点金系列看跌 两层区间 27 天结构性存 | 20,000.00 | 20,000.00 | 26.63 | - | | | 款 | | | | | | 9 | 招商银行单位大额存单 2025 年第 736 期 | 18,000.00 | 18,000.00 | 6 ...

Group 1 - The 2025 Fortune China 500 list includes 8 companies based in Nanjing, with notable rankings such as Jiangsu Bank at 162nd and Suzhou Industrial Park Holding Group at 181st [1] - Six of the listed companies improved their rankings compared to the previous year, with Huatai Securities experiencing a significant rise of 93 places [1] Group 2 - Jiangsu Bank launched a promotional campaign linked to the "Su Super" sports event, resulting in a 112% year-on-year increase in dining and tourism transaction volumes [5] - Su Ning's MAX Super Experience Store opened in Nanjing, achieving sales of over 500 million yuan on its first day, showcasing a successful integration of technology and consumer experience [6] Group 3 - Nanjing Pharmaceutical is advancing its digital transformation with a fully digitalized herbal medicine preparation system, achieving a revenue of 53.696 billion yuan in 2024, a 0.20% increase year-on-year [7] - Huitongda is promoting the digital transformation of rural stores with its "AI Super Store Manager" system, enhancing operational efficiency [8] Group 4 - Suhao Holding Group is focusing on high-end textile and hardware trade, leveraging technology to enhance cross-border e-commerce services for small and medium enterprises [9] - Nanjing Bank is innovating financial services with a focus on supporting technology enterprises, having provided over 700 billion yuan in credit support to more than 70,000 tech companies [9] Group 5 - Jiangsu Guoxin is accelerating its transformation by developing new asset management and trust services, enhancing its capability to serve the economy [10] - The Nanjing government is continuously improving the business environment, emphasizing a user-centric approach to create a high-quality service system for enterprises [10]

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its second medium-term note for 2024, with a total issuance amount of 1 billion [1] - The bond has a maturity period of 5 years and an interest rate of 2.30%, with the first interest payment scheduled for August 9, 2025, amounting to 23 million [1] - The bond is rated AA+ and is managed by China Merchants Bank Co., Ltd., which also serves as the lead underwriter [1][2] Group 2 - The interest payment process involves transferring funds to the designated account of the interbank market clearing house before the payment date, with adjustments made for public holidays [1] - The company and its board members commit to the accuracy and completeness of the announcement and will fulfill subsequent information disclosure obligations as required [2]

证券代码：600713 证券简称：南京医药 编号：ls2025-097 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2024 年度第二期中期票据 2025 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2024 年度第二期中期票据（债券简称：24 南 京医药 MTN002，债券代码：102483420.IB）付息工作的顺利进行，现将有关事 宜公告如下： | 发行人名称 | 南京医药股份有限公司 | | | --- | --- | --- | | 债项名称 | 南京医药股份有限公司 2024 年度第二期中期票据 | | | 债项简称 | 南京医药 | 24 MTN002 | | 债项代码 | 102483420.IB | | | 发行总额（亿） | 10.00 | | | 起息日 | 2024-08-09 | | | 发行期限（年） | | 5 | | 债券余额（亿） | 10.00 | | | 最新评级情况 | | AA+ | | 偿还类别 | 利息支付 | | ...

证券代码：600713 证券简称：南京医药 编号：ls2025-096 债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司本次使用部分暂时闲置募集资金 1 亿元购买结构性存款。 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期限内可以滚动使用，到期后归还至募集资金专户。 特别风险提示：尽管公司购买的结构性存款安全性较高、流动性较好、 风险较低，但金融市场受宏观经济的 ...

Core Viewpoint - Nanjing Pharmaceutical has experienced significant growth since its listing in 1996, with its market capitalization increasing from 586 million yuan to 6.623 billion yuan, reflecting the development of the pharmaceutical distribution industry, although recent years show a slowdown in growth momentum [1][3]. Business Overview - The main business of Nanjing Pharmaceutical includes the sale of pharmaceutical products, with wholesale accounting for the highest revenue share at 94.72%, followed by retail at 4.53% [3]. - Since its listing, the company has achieved a cumulative net profit growth of 1788.12%, from 30 million yuan in 1996 to 571 million yuan in 2024, with 17 years of profit growth out of 29 years [3][4]. Financial Performance - Revenue has shown steady growth, increasing from 39.817 billion yuan in 2020 to 53.696 billion yuan in 2024, although the growth rate has been gradually slowing [4]. - The net profit attributable to shareholders rose from 37.6 million yuan in 2020 to 571 million yuan in 2024, with a slight decline in the last two years indicating increased competitive pressure in the industry [4]. Market Capitalization - Since its listing, Nanjing Pharmaceutical's market capitalization has increased by 10.30 times, demonstrating long-term investment value. However, it has decreased from a peak of 18.397 billion yuan in June 2015 to 6.623 billion yuan, representing a market value loss of 11.774 billion yuan or 64% [6].

| | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/15 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 7,000万元~13,158万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,629.9951万股 | | 累计已回购股数占总股本比例 | 1.25% | | 累计已回购金额 | 8,025.76万元 | | 实际回购价格区间 | 4.69元/股~5.22元/股 | 一、回购股份的基本情况 2025 年 3 月 14 日，南京医药股份有限公司（以下简称"公司"）召开第九届董 事会 2025 年第一次临时会议，审议通过了《关于以集中竞价交易方式回购公司股 ...